What Do the New ASCCP Guidelines Mean for Clinical Labs?
KeywordsCervical Cancer, ASCCP Guidelines, HPV Testing, Self-Collection, At-Home Testing, Women's Health, Diagnostic Solutions, Preventive Care, Medical Technology, Health AccessSummaryIn this episode of Clinical Lab Chat, Chris Wolski and Dr. Jeff Andrews discuss significant advancements in cervical cancer prevention, focusing on the new ASCCP guidelines, the role of technology in screening, and the importance of self-collection methods. They explore how these changes can improve access to care for women and the future of at-home testing, while also addressing the psychological barriers and stigmas associated with cervical cancer screening.TakeawaysThe ASCCP guidelines are essential for managing cervical cancer risk.Technology has transformed how guidelines are updated and accessed.Self-collection methods can significantly increase screening rates.At-home testing is preferred by many women for convenience and privacy.Addressing stigmas is crucial for increasing testing participation.Cervical cancer is highly treatable when detected early.The Onclarity assay provides extended genotyping for better risk assessment.Guidelines are now more dynamic and can be updated quickly.Improving access to care is vital for women's health.The fight against cervical cancer is entering an exciting new phase.TitlesRevolutionizing Cervical Cancer PreventionThe Future of Women's Health ScreeningSound Bites"We can update guidelines very quickly now.""The app makes it much more dynamic and useful.""We're dealing with a couple of stigmas."Chapters00:00Introduction to New Diagnostic Guidelines02:51Understanding ASCCP Guidelines and Their Evolution05:30The Role of Technology in Women's Health Testing08:11Onclarity HPV Assay and Its Significance10:48Self-Collection Methods for Cervical Cancer Screening13:19The Future of At-Home Testing15:53Impact of New Guidelines on Labs and Testing18:32Addressing Stigmas and Psychological Barriers20:45Conclusion and Future Directions21:41Podcast Music Outro.wav
--------
21:54
Alpha-Synuclein: Adding Precision to Neurodegenerative Testing
In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion. Among the topics they discuss:The critical importance of making accurate diagnoses of neurodegenerative diseasesWhy alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’sHow adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregiversWhy we’re entering a neurological healthcare “golden age”
--------
24:03
C Diff: How Awareness Improves Diagnostics and Treatments
In this episode of Clinical Lab Chat, CLP Director of Business Intelligence Chris Wolski engages in a wide-ranging discussion with Peggy Lillis Foundation CEO and founder Christian Lillis about the organization’s efforts to raise awareness of C diff. Among the topics they discuss: Why C diff is difficult to diagnoseHow Peggy Lillis is engaging with the public, scientific community, and legislators to improve understanding, diagnostics, and treatment of this increasingly common diseaseThe parallels of these awareness efforts with other public health education effortsHow laboratorians can help their organizations develop workflows to avoid under- and over-testing for C diff.
--------
43:39
HPV Self-Sampling Is Being Put into Practice in Texas
In this episode of Clinical Lab Chat, Jeff Andrews, MD, FRCSC, BD’s VP of Global Medical Affairs for Diagnostic Solutions, makes a return visit to the studio for a conversation with CLP’s director of business intelligence, Chris Wolski, about BD and MD Anderson’s collaboration on HPV sample self-collection study. Among the topics they cover:How self-collection aids in the fight against cervical cancerThe importance of reaching underserved communitiesHow MD Anderson’s program is shining a light on the need for sampling options in the U.S. and across the worldThe business benefits self-collection brings to labsThe impact self-collection will have in the near- and long-term
--------
23:02
Will HPV Self-Collection Help Prevent Cervical Cancer?
In this episode of Clinical Lab Chat, Director of Business Intelligence Chris Wolski interviews Jeff Andrews, MD, FRCSC, a board-certified gynecologist and vice president of Global Medical Affairs for Diagnostic Solutions at BD, what HPV sample self-collection means for the diagnosis, prevention, and treatment of HPV and cervical cancer. Among the topics they cover in this wide-ranging interview:How HPV sample self-collection will improve testing and treatment access.The importance of sample integrity.The larger public health implications of making HPV and cervical cancer screening routine and accessible.The findings of a recent UN General Assembly meeting about HPV diagnosis and treatment.What it’s going to take to make cervical cancer a thing of the past.
Step into the world of clinical labs with a podcast that delves deep into both the science and the strategy. From groundbreaking diagnostic and molecular testing to the intricacies of lab management, our episodes offer a comprehensive look at the ever-evolving lab landscape. We bring you the latest in lab technology, innovative testing procedures, and key insights from industry decision-makers and influencers. Beyond the science, we also focus on the operational side of things, offering tips and trends in lab management, ensuring your lab runs efficiently and stays ahead of the curve. Whether you're deep into the world of clinical diagnostics or looking to enhance your lab's operational excellence, this podcast provides the insights you need to stay at the pinnacle of lab advancements.
Sverige